Patents by Inventor Jay K. Kolls

Jay K. Kolls has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210145948
    Abstract: A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.
    Type: Application
    Filed: May 13, 2020
    Publication date: May 20, 2021
    Applicants: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
    Inventors: Jay K. Kolls, Michael Zheng, Karen Norris, Heather Kling
  • Publication number: 20180318406
    Abstract: A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.
    Type: Application
    Filed: July 13, 2018
    Publication date: November 8, 2018
    Applicants: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
    Inventors: Jay K. Kolls, Michael Zheng, Karen Norris, Heather Kling
  • Publication number: 20170173127
    Abstract: A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fimgal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 22, 2017
    Applicants: University of Pittsburgh - of the Commonwealth System of Higher Education, Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
    Inventors: JAY K. KOLLS, Michael Zheng, Karen Norris, Heather Kling
  • Patent number: 9580704
    Abstract: A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: February 28, 2017
    Assignees: University of Pittsburgh—of the Commonwealth System of Higher Education, Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Jay K. Kolls, Michael Zheng, Karen Norris, Heather Kling
  • Publication number: 20130315857
    Abstract: A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.
    Type: Application
    Filed: August 5, 2013
    Publication date: November 28, 2013
    Applicants: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE, UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: JAY K. KOLLS, ZHENG MINQUAN, KAREN NORRIS, HEATHER KLING
  • Publication number: 20130058891
    Abstract: A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.
    Type: Application
    Filed: January 5, 2011
    Publication date: March 7, 2013
    Inventors: Jay K. Kolls, Mingquan Zheng
  • Publication number: 20100322897
    Abstract: The invention is related to findings that IL-17F-mediated inflammation of airway passages may be mediated via signaling through IL-17R on the basolateral surface of human respiratory epithelial cells. Thus, the present invention provides isolated and purified IL-17F or IL-17R polynucleotides and polypeptides. The present invention also is directed to novel methods for screening test compounds capable of inhibiting, i.e., decreasing, limiting, blocking, or otherwise reducing, IL-17F bioactivity, and methods for diagnosing, prognosing, and monitoring the progress of, disorders related to IL-17F bioactivity, e.g., disorders related to the effects of IL-17F binding to IL-17R on airway inflammation, e.g., in patients with cystic fibrosis, including pulmonary exacerbations due to bacterial infections in same. The present invention is further directed to novel therapeutics and therapeutic targets and to methods for the intervention (treatment) and prevention of said disorders related to IL-17F bioactivity.
    Type: Application
    Filed: April 26, 2010
    Publication date: December 23, 2010
    Inventors: Jay K. Kolls, Florencia Marine McAllister, Beatriz M. Carreno, Samuel J. Goldman
  • Patent number: 7704503
    Abstract: The invention is related to findings that IL-17F-mediated inflammation of airway passages may be mediated via signaling through IL-17R on the basolateral surface of human respiratory epithelial cells. Thus, the present invention provides isolated and purified IL-17F or IL-17R polynucleotides and polypeptides. The present invention also is directed to novel methods for screening test compounds capable of inhibiting, i.e., decreasing, limiting, blocking, or otherwise reducing, IL-17F bioactivity, and methods for diagnosing, prognosing, and monitoring the progress of, disorders related to IL-17F bioactivity, e.g., disorders related to the effects of IL-17F binding to IL-17R on airway inflammation, e.g., in patients with cystic fibrosis, including pulmonary exacerbations due to bacterial infections in same. The present invention is further directed to novel therapeutics and therapeutic targets and to methods for the intervention (treatment) and prevention of said disorders related to IL-17F bioactivity.
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: April 27, 2010
    Assignees: Wyeth LLC, University of Pittsburgh of the Commonwealth System of Higher Education
    Inventors: Jay K. Kolls, Florencia Marine McAllister, Beatriz M. Carreno, Samuel J. Goldman